ArticleFrontiers in pharmacology2025
Knowledge structure and dynamic evolution of nanomedicine in liver cancer research: a scientometric analysis and visualization.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nanomedicine has received much attention for its potential applications in the diagnosis and treatment of liver cancer. However, no bibliometric evaluation has been conducted to present an assessment of scientific progress in the field. The aim of this study is to comprehensively catalog the cooperation and influence of journals, countries, institutions, and authors in the field of nanomedicine in liver cancer from the perspective of bibliometrics, evaluate the clustering evolution of knowledge structure, and uncover hot topics and emerging themes. Methods: Articles and reviews related to nanomedicine and liver cancer were retrieved from the Web of Science Core Literature Library using Topic Search. #1 T= ("Hepatic Neoplasm*" OR "Liver Neoplasm" OR "Liver Cancer*" OR "Hepatocellular Cancer*" OR "Hepatic Cancer*"), #2 T= "nano*", the search strategy is set as #1 AND #2 limited to Science Citation Index Expanded database source, with no limitation of publication types and language/time. Bibliometric studies were conducted using CiteSpace and VOSviewer. Results: 2,648 articles and reviews were included from 2000 to 2024. The number of articles regarding nanomedicine in liver cancer showed an increasing trend. Analysis of the most productive journals shows that most are specialized in nanoscience and nanotechnology, pharmacology and pharmacy, and chemistry and multidisciplinary. These publications mainly come from 8,782 institutions in 297 countries led by China and the United States of America. Shao D published the most papers among the publications, while Jemal A had the most co-citations. The macroscopical sketch and micro-representation of the whole knowledge field are realized through co-citation analysis. Hepatocellular carcinoma, targeted delivery, sorafenib nanoparticles, and others are current and developing areas of study. The keywords "nanocrystals," "biodistribution," and "particles" also may be the focus of new trends and future research. Conclusion: In this study, bibliometrics and visual methods were used to review the research of nanomedicine in liver cancer comprehensively. The article will help scholars to gain a better understanding of the dynamic evolution of nanomedicine applications in liver cancer and point the directions for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.